UFT monotherapy as adjuvant chemotherapy for HER2 negative breast cancer patients who did not achieve pathologic complete response (non-pCR) after neoadjuvant chemotherapy: Phase 2 study.
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2014
At a glance
- Drugs Tegafur/uracil (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 28 Jan 2014 According to University Hospital Medical Information Network - Japan record, status changed from recruiting to discontinued.
- 10 Jan 2012 New trial record